Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer

NCT01577654 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

203

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: EC145
DRUG: EC145 + Docetaxel
DRUG: Docetaxel
DRUG: EC20

Sponsor

Endocyte